Paul Maroni, MD
Associate Professor, Surgery-Urology

Photo
Medical School:
  • MD, University of Illinois College of Medicine (2000)
Undergraduate School:
  • BA, University of Virginia (VA) (1996)
Residencies:
  • University of Colorado (University Hospital) Program, Urology (2006)
  • University of Colorado (University Hospital) Program, Surgery (2002)
Fellowships:
  • Indiana University School of Medicine Program, Urologic Oncology (2007)
Languages: English
Department: Surgery-Urology

Professional Titles

  • Clinical Director of Urologic Oncology

Recognition & Awards

  • Top Doc, 5280 Magazine (2019)
  • Top Doc, 5280 Magazine (2016)
  • Top Doc, 5280 Magazine (2015)
  • Top Doc, 5280 Magazine (2014)
    Peer selected award for top 4 urologist in Denver Metro Area

Research Interests

I focus on studying quality of life outcomes for patients with prostate cancer and testicular cancer. The ultimate goal is a patient that survives the cancer and returns to a "better than" normal state. A cancer diagnosis is an opportunity to engage in other healthy behaviors.

Teaching

  • Associate Professor (2007)
    School of Medicine, Surgery
    Prostate Cancer, Testicular Cancer, Kidney Cancer, Robotic Surgery

Publications

  • Raina K, Kandhari K, Kant R, Prasad RR, Mishra N, Maurya AK, Fox JT, Sei S, Shoemaker RH, Bosland MC, Maroni P, Agarwal C, Agarwal R. Differential Effect of Non-Steroidal Anti-Inflammatory Drugs Aspirin and Naproxen against TMPRSS2-ERG (Fusion)-Driven and Non-Fusion-Driven Prostate Cancer. Cancers (Basel). 2023 Oct 19;15(20). PubMed PMID: 37894421
  • Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall'Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Maroni P, Ponsky L, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Smaldone MC, Sonn G, Tyson MD, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi RA, Freedman-Cass DA. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. J Natl Compr Canc Netw. 2023 Mar;21(3):236-246. PubMed PMID: 36898362
  • Raina K, Kandhari K, Jain AK, Ravichandran K, Maroni P, Agarwal C, Agarwal R. Stage-Specific Effect of Inositol Hexaphosphate on Cancer Stem Cell Pool during Growth and Progression of Prostate Tumorigenesis in TRAMP Model. Cancers (Basel). 2022 Aug 30;14(17). PubMed PMID: 36077751
  • Meier KM, Meyers ML, Fishbein LM, Maroni PD, Cost NG. Multifocal Paraganglioma in Teenager Presenting with Hypertension. Urology. 2022 Oct 22. [Epub ahead of print] PubMed PMID: 36283505
  • Raina K, Kant R, Prasad RR, Kandhari K, Tomar M, Mishra N, Kumar R, Fox JT, Sei S, Shoemaker RH, Chen Y, Maroni P, Agarwal C, Agarwal R. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models. Mol Carcinog. 2022 Jul;61(7):717-734. PubMed PMID: 35452553
  • Raina K, Kandhari K, Jain AK, Ravichandran K, Maroni P, Agarwal C, Agarwal R. Stage-Specific Effect of Inositol Hexaphosphate on Cancer Stem Cell Pool during Growth and Progression of Prostate Tumorigenesis in TRAMP Model. Cancers (Basel). 2022 Aug 30;14(17). PubMed PMID: 36077751
  • Raina K, Kant R, Prasad RR, Kandhari K, Tomar M, Mishra N, Kumar R, Fox JT, Sei S, Shoemaker RH, Chen Y, Maroni P, Agarwal C, Agarwal R. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models. Mol Carcinog. 2022 Jul;61(7):717-734. PubMed PMID: 35452553
  • Prasad RR, Raina K, Mishra N, Tomar MS, Kumar R, Palmer AE, Maroni P, Agarwal R. Stage-specific differential expression of zinc transporter SLC30A and SLC39A family proteins during prostate tumorigenesis. Mol Carcinog. 2022 May;61(5):454-471. PubMed PMID: 35049094
  • Johnson TR, Koul S, Kumar B, Khandrika L, Venezia S, Maroni PD, Meacham RB, Koul HK. Retraction Note to: Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: Regulation of MMP 9 by PDEF. Mol Cancer. 2021 Aug 27;20(1):109. PubMed PMID: 34452613
  • Makedon A, Maroni P. Median Lobe Urethral Embolus After Focal Ablation of Gleason 7 Prostate Cancer. Oncology (Williston Park). 2021 Jul 13;35(7):422-424. PubMed PMID: 34264568
  • Pessoa RR, Maroni P, Kukreja J, Kim SP. Comparative effectiveness of robotic and open radical prostatectomy. Transl Androl Urol. 2021 May;10(5):2158-2170. PubMed PMID: 34159098
  • Rodrigues Pessoa R, Morrison JC, Konety B, Gershman B, Maroni P, Kukreja JB, Cost N, Flaig T, Kessler E, Sharma P, Kim SP. National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy. Urol Oncol. 2021 Dec;39(12):832.e9-832.e15. PubMed PMID: 33820697
  • Makedon A, Maroni P. Median Lobe Urethral Embolus After Focal Ablation of Gleason 7 Prostate Cancer. Oncology (Williston Park). 2021 Jul 13;35(7):422-424. PubMed PMID: 34264568
  • Pessoa RR, Maroni P, Kukreja J, Kim SP. Comparative effectiveness of robotic and open radical prostatectomy. Transl Androl Urol. 2021 May;10(5):2158-2170. PubMed PMID: 34159098
  • Rodrigues Pessoa R, Morrison JC, Konety B, Gershman B, Maroni P, Kukreja JB, Cost N, Flaig T, Kessler E, Sharma P, Kim SP. National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy. Urol Oncol. 2021 Dec;39(12):832.e9-832.e15. PubMed PMID: 33820697
  • Stanton WN, Crawford ED, Arangua PB, La Rosa FG, van Bokhoven A, Lucia MS, Poage WL, Partin A, Maroni P, Werahera PN. Assessment of high-grade prostate cancer risk using prostate cancer biomarkers. Can J Urol. 2020 Feb;27(1):10080-10085. PubMed PMID: 32065862
  • Maroni P. Editorial Comment. J Urol. 2020 Oct;204(4):810. PubMed PMID: 32898978
  • Sheridan A, Maroni P, Patel NU. Tips to start an MR-US fusion biopsy program. Abdom Radiol (NY). 2020 Dec;45(12):4023-4027. PubMed PMID: 32504131
  • Stanton WN, Crawford ED, Arangua PB, La Rosa FG, van Bokhoven A, Lucia MS, Poage WL, Partin A, Maroni P, Werahera PN. Assessment of high-grade prostate cancer risk using prostate cancer biomarkers. Can J Urol. 2020 Feb;27(1):10080-10085. PubMed PMID: 32065862
  • Gore JL, du Plessis M, Zhang J, Dai D, Thompson DJS, Karsh L, Lane B, Franks M, Chen DYT, Bianco FJ Jr, Brown G, Clark W, Kibel AS, Kim H, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Spratt DE, Davicioni E, Lotan Y, Lin DW. Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. Pract Radiat Oncol. 2020 Mar - Apr;10(2):e82-e90. PubMed PMID: 31761540
  • Maroni P. Editorial Comment. J Urol. 2020 Oct;204(4):810. PubMed PMID: 32898978
  • Sheridan A, Maroni P, Patel NU. Tips to start an MR-US fusion biopsy program. Abdom Radiol (NY). 2020 Dec;45(12):4023-4027. PubMed PMID: 32504131
  • Gore JL, du Plessis M, Zhang J, Dai D, Thompson DJS, Karsh L, Lane B, Franks M, Chen DYT, Bianco FJ Jr, Brown G, Clark W, Kibel AS, Kim H, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Spratt DE, Davicioni E, Lotan Y, Lin DW. Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. Pract Radiat Oncol. 2020 Mar - Apr;10(2):e82-e90. PubMed PMID: 31761540
  • Stanton WN, Crawford ED, Arangua PB, La Rosa FG, van Bokhoven A, Lucia MS, Poage WL, Partin A, Maroni P, Werahera PN. Assessment of high-grade prostate cancer risk using prostate cancer biomarkers. Can J Urol. 2020 Feb;27(1):10080-10085. PubMed PMID: 32065862
  • Gore JL, du Plessis M, Zhang J, Dai D, Thompson DJS, Karsh L, Lane B, Franks M, Chen DYT, Bianco FJ Jr, Brown G, Clark W, Kibel AS, Kim H, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Spratt DE, Davicioni E, Lotan Y, Lin DW. Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. Pract Radiat Oncol. 2019 Nov 20. [Epub ahead of print] PubMed PMID: 31761540
  • Aasen DM, Wiedel C, Maroni P, Cohen ME, Meng X, Meguid RA. Association of Hospital Altitude and Postoperative Infectious Complications After Major Operations. High Alt Med Biol. 2019 Dec;20(4):421-426. PubMed PMID: 31618098
  • Bidikov L, Maroni P, Kim S, Crawford ED. 67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant Potential. Oncology (Williston Park). 2019 Sep 20;33(9). PubMed PMID: 31571179
  • Tyagi A, Kumar S, Raina K, Wempe MF, Maroni PD, Agarwal R, Agarwal C. Differential effect of grape seed extract and its active constituent procyanidin B2 3,3?-di-O-gallate against prostate cancer stem cells. Mol Carcinog. 2019 Jul;58(7):1105-1117. PubMed PMID: 30828884
  • Gershman B, Maroni P, Tilburt JC, Volk RJ, Konety B, Bennett CL, Kutikov A, Smaldone MC, Chen V, Kim SP. A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World J Urol. 2019 Oct;37(10):2099-2108. PubMed PMID: 30671637
  • Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY. A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol. 2019 Apr;201(4):682-692. PubMed PMID: 30077557
  • Aasen DM, Wiedel C, Maroni P, Cohen ME, Meng X, Meguid RA. Association of Hospital Altitude and Postoperative Infectious Complications After Major Operations. High Alt Med Biol. 2019 Dec;20(4):421-426. PubMed PMID: 31618098
  • Bidikov L, Maroni P, Kim S, Crawford ED. 67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant Potential. Oncology (Williston Park). 2019 Sep 20;33(9). PubMed PMID: 31571179
  • Tyagi A, Kumar S, Raina K, Wempe MF, Maroni PD, Agarwal R, Agarwal C. Differential effect of grape seed extract and its active constituent procyanidin B2 3,3?-di-O-gallate against prostate cancer stem cells. Mol Carcinog. 2019 Jul;58(7):1105-1117. PubMed PMID: 30828884
  • Gershman B, Maroni P, Tilburt JC, Volk RJ, Konety B, Bennett CL, Kutikov A, Smaldone MC, Chen V, Kim SP. A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World J Urol. 2019 Oct;37(10):2099-2108. PubMed PMID: 30671637
  • Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY. A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol. 2019 Apr;201(4):682-692. PubMed PMID: 30077557
  • Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET. Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther. 2018 Dec;17(4):1103-1108. PubMed PMID: 30289005
  • Robin TP, Maroni PD, Chin BB, La Rosa FG, Bernard B, Pugh TJ. Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy Intensification. Oncology (Williston Park). 2018 Jul 15;32(7):360-3, 369, CV3. PubMed PMID: 30080921
  • Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY. A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence [RADAR] III). J Urol. 2018 Aug 2. [Epub ahead of print] PubMed PMID: 30077557
  • Maccini MA, Westfall NJ, Van Bokhoven A, Lucia MS, Poage W, Maroni PD, Wilson SS, Glodé LM, Arangua P, Newmark J, Steiner M, Werahera PN, Crawford ED. The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer. Prostate. 2018 May;78(7):506-511. PubMed PMID: 29460452
  • Jackson MW, Amini A, Jones BL, Kavanagh B, Maroni P, Frank SJ, Mahmood U, Kudchadker RJ, Pugh TJ. Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic Group 4 (Gleason score 8) prostate cancer. Brachytherapy. 2017 Jul - Aug;16(4):790-796. PubMed PMID: 28442277
  • Gore JL, du Plessis M, Santiago-Jiménez M, Yousefi K, Thompson DJS, Karsh L, Lane BR, Franks M, Chen DYT, Bandyk M, Bianco FJ Jr, Brown G, Clark W, Kibel AS, Kim HL, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Davicioni E, Lotan Y, Lin DW. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study. Cancer. 2017 Aug 1;123(15):2850-2859. PubMed PMID: 28422278
  • Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ. Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. Urol Oncol. 2017 Jun;35(6):438-446. PubMed PMID: 28214281
  • Stokes W, Amini A, Maroni PD, Kessler ER, Stokes C, Cost CR, Greffe BS, Garrington TP, Liu AK, Cost NG. Patterns of care and survival outcomes for adolescent and young adult patients with testicular seminoma in the United States: A National Cancer Database analysis. J Pediatr Urol. 2017 Aug;13(4):386.e1-386.e7. PubMed PMID: 28153774
  • Amini A, Waxweiler TV, Maroni PD, Kessler ER, Cost CR, Greffe BS, Garrington TP, Liu AK, Cost NG. Survival outcomes of adolescent and adult patients with non-seminomatous testicular germ-cell tumors: A population-based study. J Pediatr Urol. 2016 Dec;12(6):405.e1-405.e9. PubMed PMID: 27544905
  • Rove KO, Maroni PD, Cost CR, Fairclough DL, Giannarini G, Harris AK, Schultz KA, Cost NG. Pathologic Risk Factors for Metastatic Disease in Postpubertal Patients With Clinical Stage I Testicular Stromal Tumors. Urology. 2016 Nov;97:138-144. PubMed PMID: 27538802
  • Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Kim S, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Vickers AJ, Wake R, Shead DA, Freedman-Cass DA. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. J Natl Compr Canc Netw. 2016 May;14(5):509-19. PubMed PMID: 27160230
  • Amini A, Jones BL, Jackson MW, Rusthoven CG, Maroni P, Kavanagh BD, Raben D. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base. Brachytherapy. 2016 Mar-Apr;15(2):136-46. PubMed PMID: 26825856
  • Amini A, Jones B, Jackson MW, Yeh N, Waxweiler TV, Maroni P, Kavanagh BD, Raben D. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base. J Urol. 2016 May;195(5):1453-8. PubMed PMID: 26576709
  • Werahera PN, Jasion EA, Crawford ED, Lucia MS, van Bokhoven A, Sullivan HT, Kim FJ, Maroni PD, Port JD, Daily JW, La Rosa FG. Diffuse reflectance spectroscopy can differentiate high grade and low grade prostatic carcinoma. Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:5148-5151. PubMed PMID: 28325017
  • Schlaepfer IR, Glodé LM, Hitz CA, Pac CT, Boyle KE, Maroni P, Deep G, Agarwal R, Lucia SM, Cramer SD, Serkova NJ, Eckel RH. Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[(18)F]Fluoro-D-Glucose Uptake in Prostate Cancer Mouse Xenografts. Mol Imaging Biol. 2015 Jan 6. [Epub ahead of print] PubMed PMID: 25561013
  • Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenke P, Vickers AJ, Wake R, Shead DA, Freedman-Cass D. Prostate Cancer Early Detection, Version 2.2015. J Natl Compr Canc Netw. 2015 Dec;13(12):1534-61. PubMed PMID: 26656522
  • Amini A, Jones B, Jackson MW, Yeh N, Waxweiler TV, Maroni P, Kavanagh BD, Raben D. Survival Outcomes of Dose-Escalated External Beam Radiotherapy (DE-EBRT) Versus Combined Brachytherapy for Intermediate- and High-Risk Prostate Cancer Using the National Cancer Data Base. J Urol. 2015 Nov 11. [Epub ahead of print] PubMed PMID: 26576709
  • Rove KO, Maroni PD, Cost CR, Fairclough DL, Giannarini G, Harris AK, Schultz KA, Cost NG. Pathologic Risk Factors in Pediatric and Adolescent Patients With Clinical Stage I Testicular Stromal Tumors. J Pediatr Hematol Oncol. 2015 Nov;37(8):e441-6. PubMed PMID: 26479987
  • Schlaepfer IR, Nambiar DK, Ramteke A, Kumar R, Dhar D, Agarwal C, Bergman B, Graner M, Maroni P, Singh RP, Agarwal R, Deep G. Hypoxia induces triglycerides accumulation in prostate cancer cells and extracellular vesicles supporting growth and invasiveness following reoxygenation. Oncotarget. 2015 Sep 8;6(26):22836-56. PubMed PMID: 26087400
  • Maroni PD. Is radical prostatectomy appropriate for very-high-risk prostate cancer patients? Yes. Oncology (Williston Park). 2015 May;29(5):348, 388. PubMed PMID: 25979543
  • Schlaepfer IR, Glodé LM, Hitz CA, Pac CT, Boyle KE, Maroni P, Deep G, Agarwal R, Lucia SM, Cramer SD, Serkova NJ, Eckel RH. Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[(18)F]Fluoro-D-Glucose Uptake in Prostate Cancer Mouse Xenografts. Mol Imaging Biol. 2015 Aug;17(4):529-38. PubMed PMID: 25561013
  • Hammond KP, Nielsen C, Linnebur SA, Langness JA, Ray G, Maroni P, Kiser JJ. Priapism induced by boceprevir-CYP3A4 inhibition and a-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8. PubMed PMID: 24092799
  • Werahera PN, Jasion EA, Crawford ED, La Rosa FG, Lucia MS, van Bokhoven A, Sullivan HT, Port JD, Maroni PD, Daily JW. Systematic diagnosis of prostate cancer using an optical biopsy needle adjunct with fluorescence spectroscopy. Conf Proc IEEE Eng Med Biol Soc. 2014;2014:2165-8. PubMed PMID: 25570414
  • Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Sep;12(9):1211-9; quiz 1219. PubMed PMID: 25190691
  • Cost NG, Maroni P, Flaig TW. Metastatic relapse after initial clinical stage I testicular Leydig cell tumor. Oncology (Williston Park). 2014 Mar;28(3):211, 214. PubMed PMID: 24855728
  • Rusthoven CG, Carlson JA, Waxweiler TV, Raben D, Dewitt PE, Crawford ED, Maroni PD, Kavanagh BD. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1064-73. PubMed PMID: 24661660
  • Maroni P, Moss J. Nephron-sparing surgery. Semin Intervent Radiol. 2014 Mar;31(1):104-6. PubMed PMID: 24596448
  • Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate. 2013 May;73(7):778-87. PubMed PMID: 23169245
  • Garrett K, Okuyama S, Jones W, Barnes D, Tran Z, Spencer L, Lewis K, Maroni P, Chesney M, Marcus A. Bridging the transition from cancer patient to survivor: pilot study results of the Cancer Survivor Telephone Education and Personal Support (C-STEPS) program. Patient Educ Couns. 2013 Aug;92(2):266-72. PubMed PMID: 23647980
  • Maroni P. In germ cell cancer, are we at the end of the chemotherapy era? Maybe--and we are certainly at the end of the RCT era. Oncology (Williston Park). 2013 Nov;27(11):1136, 1143. PubMed PMID: 24575541
  • Maroni P, Phillips JM. Hopes and dreams for quality improvement in radical prostatectomy. Oncology (Williston Park). 2012 Jul;26(7):630, 635. PubMed PMID: 22888563
View All (66 Total) View Less

Professional Memberships

  • American Urological Association, Member
  • Rocky Mountain Urological Society, Member
  • Southwest Oncology Group, Member
  • University of Colorado Comprehensive Cancer Center, Member
  • Society of Urologic Oncology, Member

Practice Locations

UCHealth Tony Grampsas Urologic Cancer Care Clinic - Anschutz Medical Campus
1665 Aurora Ct
1st Floor
Aurora, CO 80045
720-848-0170

CU Medicine Urologic Oncology - Highlands Ranch Specialty Care Center
1500 Park Central Drive
Suite 201
Highlands Ranch, CO 80129
720-516-1094

Hospital Affiliation
  • University of Colorado Hospital
  • UCHealth Highlands Ranch Hospital
Center Affiliations

Specialty Information

Specialties
  • Urology, Board Certification (, 2009)
  • Urologic Oncology
  • MD, License (2000)
Conditions & Treatments
  • Surgery
  • Surgery - Robotic Surgery
  • Cancers - Kidney Cancer
  • Cancers - Prostate Cancer
  • Cancers - Testicular Cancer
  • Surgery - Urologic Surgery
  • Cancers - Urologic Cancer
  • Cancers
  • Transgender Health
  • Men's Health - Prostate Conditions
  • Men's Health
Clinical Interests
My main interests are robotic or daVinci surgery for prostate or kidney cancer. I have done over 1000 robotic prostate removals (as of 2020). I care a great deal about doing a good job with this operation including nerve-sparing surgery when appropriate. I also specialize in complex abdominal surgery for metastatic testicular cancer. This operation is called Retroperitoneal Lymph Node Dissection or RPLND. Testimonial from a prostate cancer patient: "Please feel free to use my story as needed to reassure future Prostate Cancer victims...and Radical Prostatectomy candidates/patients in general...that there is indeed life after a cancer diagnosis and that a Prostatectomy (at least one done with your skills) won't keep them from taking on strenuous physical challenges." I also treat men with enlargement of the prostate gland. I perform a number of procedures including Holmium Laser Enucleation of the Prostate or HoLEP. HoLEP is a great operation for men with prostate enlargement.

Care Philosophy
A diagnosis of cancer is awful. I view the patient relationship as a partnership and focus on educating in clear terms. I try my best to give every patient the time they deserve. We use a team approach to provide the very best cancer care!

Personal Interests
In my spare time, I enjoy spending time with my family, long-distance running, snowboarding, and biking.

Public Speaking
Yes
I speak at regional and national meetings about physician wellness and burnout.

General Information

Medical Schools:
  • MD, University of Illinois College of Medicine (2000)
Undergraduate Schools:
  • BA, University of Virginia (VA) (1996)
Residency Programs:
  • University of Colorado (University Hospital) Program, Urology (2006)
  • University of Colorado (University Hospital) Program, Surgery (2002)
Fellowships:
  • Indiana University School of Medicine Program, Urologic Oncology (2007)
Languages: English
Department: Surgery-Urology
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;